<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig4">
 <label>Figure 4</label>
 <caption>
  <p>Dose-dependent anti-SARS-CoV-2 effects of panduratin A and remdesivir in human airway epithelial cells (Calu-3) at the post-entry phase. (
   <bold>a</bold>) High-content imaging analysis of panduratin A (
   <bold>a</bold>) and remdesivir (
   <bold>b</bold>) (the left panel). The percentage of virus inhibition (blue) and cell viability (red) was shown in the right panel (n = 3 biological replicates). Fluorescent signals: green, anti-SARS-CoV-2 NP mAb; blue, Hoechst. (
   <bold>c</bold>, 
   <bold>d</bold>) Plaque reduction assay of panduratin A (
   <bold>c</bold>) remdesivir (
   <bold>d</bold>). (
   <bold>e</bold>) Comparison of IC
   <sub>50</sub> values of panduration A and remdesivir evaluated by IFA of the high-content imaging technique and plaque assay in two cell types, Vero E6 and Calu-3.
  </p>
 </caption>
 <graphic xlink:href="41598_2020_77003_Fig4_HTML" id="MO4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
